Publications by authors named "R Bissonnette"
Article Synopsis
- Ruxolitinib cream, shown to be safe and effective in a phase 3 study, has demonstrated its anti-inflammatory and itch-relieving properties in children aged 2-11 with mild to moderate atopic dermatitis (AD).
- The study focused on assessing safety, tolerability, pharmacokinetics, and quality of life while using the cream at maximum levels over longer periods, with 29 children participating and applying the cream twice daily for 4 weeks, followed by individualized usage.
- Results indicated that 31% of participants experienced treatment-related adverse events, but no severe health issues arose, and significant improvements in skin condition and quality of life were sustained for up to 52 weeks.
Introduction: Chronic hand eczema (CHE) is a highly prevalent inflammatory skin condition which is often resistant to conventional treatments. Molecular insights of CHE remain limited. Tape stripping combined with high-throughput RNA sequencing can now provide a better insight into CHE pathogenesis in a minimally invasive fashion.
View Article and Find Full Text PDFThe National Psoriasis Foundation (NPF) treatment targets aim to achieve 1% or lower body surface area (BSA) affected after 3 months of treatment. European psoriasis treatment guidelines aim to achieve similar goals based on improvements in Psoriasis Area and Severity Index (PASI) scores. We performed pooled analyses of the PSOARING phase 3 program, which evaluated treat-to-target outcomes for patients treated with tapinarof cream 1% once daily (QD) for up to 52 weeks.
View Article and Find Full Text PDFLanguage exposure is an important determiner of language outcomes in bilingual children. Family language strategies (FLS, e.g.
View Article and Find Full Text PDFBackground: More patients with moderate-to-severe plaque psoriasis achieved responses with JNJ-77242113, a targeted oral peptide inhibiting interleukin-23 receptor signaling, versus placebo (PBO) at week (W)16 of the phase 2 FRONTIER-1 study.
Objective: FRONTIER-2, a long-term extension of FRONTIER-1, evaluated JNJ-77242113 through 1 year.
Methods: FRONTIER-1 participants received JNJ-77242113 at doses from 25 mg daily to 100 mg twice daily or PBO through W16.